10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of 10x Genomics, Inc. (NASDAQ:TXG) have been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $29.19.

A number of equities analysts have issued reports on TXG shares. The Goldman Sachs Group decreased their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. UBS Group dropped their target price on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Morgan Stanley dropped their target price on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Stephens restated an “overweight” rating and set a $30.00 target price on shares of 10x Genomics in a report on Thursday, October 10th. Finally, Barclays dropped their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, November 1st.

10x Genomics Trading Down 4.8 %

Shares of NASDAQ:TXG opened at $15.23 on Friday. The company has a 50-day moving average price of $16.53 and a 200-day moving average price of $19.35. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -9.95 and a beta of 1.84. 10x Genomics has a 12 month low of $12.95 and a 12 month high of $57.90.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The company had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) earnings per share. As a group, research analysts forecast that 10x Genomics will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after acquiring an additional 42,777 shares during the last quarter. M&T Bank Corp bought a new position in shares of 10x Genomics during the 3rd quarter valued at approximately $203,000. Barclays PLC boosted its position in shares of 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock valued at $13,605,000 after acquiring an additional 63,079 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of 10x Genomics during the 3rd quarter valued at approximately $402,000. Finally, XTX Topco Ltd boosted its position in shares of 10x Genomics by 241.9% during the 3rd quarter. XTX Topco Ltd now owns 45,008 shares of the company’s stock valued at $1,016,000 after acquiring an additional 31,844 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.